{
  "DOI": "10.1007/s00439-011-1010-0",
  "ISSN": [
    "0340-6717",
    "1432-1203"
  ],
  "URL": "http://dx.doi.org/10.1007/s00439-011-1010-0",
  "alternative-id": [
    "1010"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "20 March 2011"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "16 May 2011"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "5 June 2011"
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Biankin",
      "given": "Andrew V.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Hudson",
      "given": "Thomas J.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2011,
        6,
        4
      ]
    ],
    "date-time": "2011-06-04T07:26:00Z",
    "timestamp": 1307172360000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        7,
        29
      ]
    ],
    "date-time": "2022-07-29T02:11:55Z",
    "timestamp": 1659060715000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        1,
        25
      ]
    ],
    "date-time": "2024-01-25T17:02:42Z",
    "timestamp": 1706202162845
  },
  "is-referenced-by-count": 31,
  "issn-type": [
    {
      "type": "print",
      "value": "0340-6717"
    },
    {
      "type": "electronic",
      "value": "1432-1203"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2011,
        6,
        5
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2011,
          7
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://www.springer.com/tdm",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2011,
            6,
            5
          ]
        ],
        "date-time": "2011-06-05T00:00:00Z",
        "timestamp": 1307232000000
      }
    },
    {
      "URL": "https://www.springer.com/tdm",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2011,
            6,
            5
          ]
        ],
        "date-time": "2011-06-05T00:00:00Z",
        "timestamp": 1307232000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s00439-011-1010-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s00439-011-1010-0/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s00439-011-1010-0",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s00439-011-1010-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "79-91",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2011,
        6,
        5
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2011,
        6,
        5
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2011,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1038/nm0311-231",
      "doi-asserted-by": "crossref",
      "key": "1010_CR38",
      "unstructured": "(2011a) Cancer drugs: remedy required. Nat Med 17:231"
    },
    {
      "DOI": "10.1038/nrd3363",
      "doi-asserted-by": "crossref",
      "key": "1010_CR1",
      "unstructured": "(2011b) Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov 10:86. http://www.nature.com/nrd/journal/v10/n2/index.html"
    },
    {
      "DOI": "10.1200/JCO.2009.21.9170",
      "author": "CJ Allegra",
      "doi-asserted-by": "publisher",
      "first-page": "2091",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR2",
      "unstructured": "Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nrclinonc.2011.4",
      "author": "F Andre",
      "doi-asserted-by": "publisher",
      "first-page": "171",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR3",
      "unstructured": "Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L (2011) Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 8:171–176",
      "volume": "8",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nrd3375",
      "author": "J Arrowsmith",
      "doi-asserted-by": "publisher",
      "first-page": "87",
      "journal-title": "Nat Rev Drug Discov",
      "key": "1010_CR4",
      "unstructured": "Arrowsmith J (2011) Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Discov 10:87",
      "volume": "10",
      "year": "2011"
    },
    {
      "DOI": "10.1016/S0140-6736(10)61121-X",
      "author": "YJ Bang",
      "doi-asserted-by": "publisher",
      "first-page": "687",
      "journal-title": "Lancet",
      "key": "1010_CR5",
      "unstructured": "Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-10-2940",
      "author": "SE Bates",
      "doi-asserted-by": "publisher",
      "first-page": "5950",
      "journal-title": "Clin Cancer Res",
      "key": "1010_CR6",
      "unstructured": "Bates SE (2010) Striving to improve outcomes in oncology: unmet expectations in a complex disease. Clin Cancer Res 16:5950",
      "volume": "16",
      "year": "2010"
    },
    {
      "DOI": "10.1371/journal.pcbi.0030225",
      "author": "N Beerenwinkel",
      "doi-asserted-by": "publisher",
      "first-page": "e225",
      "journal-title": "PLoS Comput Biol",
      "key": "1010_CR7",
      "unstructured": "Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3:e225",
      "volume": "3",
      "year": "2007"
    },
    {
      "author": "P Buchler",
      "first-page": "1125",
      "journal-title": "Int J Oncol",
      "key": "1010_CR8",
      "unstructured": "Buchler P, Reber HA, Eibl G, Roth MA, Buchler MW, Friess H, Isacoff WH, Hines OJ (2005) Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 27:1125–1130",
      "volume": "27",
      "year": "2005"
    },
    {
      "DOI": "10.1097/00000421-200010000-00021",
      "author": "PA Burch",
      "doi-asserted-by": "crossref",
      "first-page": "534",
      "journal-title": "Am J Clin Oncol",
      "key": "1010_CR9",
      "unstructured": "Burch PA, Ghosh C, Schroeder G, Allmer C, Woodhouse CL, Goldberg RM, Addo F, Bernath AM, Tschetter LK, Windschitl HE, Cobau CD (2000) Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 23:534–537",
      "volume": "23",
      "year": "2000"
    },
    {
      "DOI": "10.1200/JCO.1997.15.6.2403",
      "author": "HA Burris 3rd",
      "doi-asserted-by": "crossref",
      "first-page": "2403",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR10",
      "unstructured": "Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413",
      "volume": "15",
      "year": "1997"
    },
    {
      "DOI": "10.1007/s10549-008-0128-9",
      "author": "T Byrski",
      "doi-asserted-by": "publisher",
      "first-page": "359",
      "journal-title": "Breast Cancer Res Treat",
      "key": "1010_CR11",
      "unstructured": "Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod S (2009) Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115:359–363",
      "volume": "115",
      "year": "2009"
    },
    {
      "DOI": "10.5858/2010-0567-RA.1",
      "author": "PT Cagle",
      "doi-asserted-by": "crossref",
      "first-page": "110",
      "journal-title": "Arch Pathol Lab Med",
      "key": "1010_CR12",
      "unstructured": "Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM (2011) Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 135:110–116",
      "volume": "135",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nrd3385",
      "author": "G Caponigro",
      "doi-asserted-by": "publisher",
      "first-page": "179",
      "journal-title": "Nat Rev Drug Discov",
      "key": "1010_CR13",
      "unstructured": "Caponigro G, Sellers WR (2011) Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov 10:179–187",
      "volume": "10",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nature06914",
      "author": "L Chin",
      "doi-asserted-by": "publisher",
      "first-page": "553",
      "journal-title": "Nature",
      "key": "1010_CR14",
      "unstructured": "Chin L, Gray JW (2008) Translating insights from the cancer genome into clinical practice. Nature 452:553–563",
      "volume": "452",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nm.2323",
      "author": "L Chin",
      "doi-asserted-by": "publisher",
      "first-page": "297",
      "journal-title": "Nat Med",
      "key": "1010_CR15",
      "unstructured": "Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297–303",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1155/2010/891059",
      "doi-asserted-by": "crossref",
      "key": "1010_CR16",
      "unstructured": "Clark-Knowles KV, O’Brien AM, Weberpals JI (2010) BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer. J Oncol 2010:891059"
    },
    {
      "DOI": "10.1200/JCO.2004.12.994",
      "author": "C Cordon-Cardo",
      "doi-asserted-by": "publisher",
      "first-page": "975",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR17",
      "unstructured": "Cordon-Cardo C (2004) p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol 22:975–977",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1056/NEJMra072367",
      "author": "CM Croce",
      "doi-asserted-by": "publisher",
      "first-page": "502",
      "journal-title": "N Engl J Med",
      "key": "1010_CR18",
      "unstructured": "Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511",
      "volume": "358",
      "year": "2008"
    },
    {
      "DOI": "10.1002/cncr.25393",
      "author": "G da Cunha Santos",
      "doi-asserted-by": "publisher",
      "first-page": "5599",
      "journal-title": "Cancer",
      "key": "1010_CR19",
      "unstructured": "da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS (2010) Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116:5599–5607",
      "volume": "116",
      "year": "2010"
    },
    {
      "DOI": "10.1200/JCO.2010.31.1472",
      "author": "JH Doroshow",
      "doi-asserted-by": "publisher",
      "first-page": "4869",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR20",
      "unstructured": "Doroshow JH (2010) Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 28:4869–4871",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1016/S0140-6736(05)66544-0",
      "author": "EBCTCG",
      "doi-asserted-by": "publisher",
      "first-page": "1687",
      "journal-title": "Lancet",
      "key": "1010_CR21",
      "unstructured": "EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717",
      "volume": "365",
      "year": "2005"
    },
    {
      "DOI": "10.1038/nrd3199",
      "doi-asserted-by": "crossref",
      "key": "1010_CR22",
      "unstructured": "Editorial (2010) Trial watch: adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nat Rev Drug Discov 9:423"
    },
    {
      "DOI": "10.1038/nrclinonc.2009.216",
      "author": "FJ Esteva",
      "doi-asserted-by": "publisher",
      "first-page": "98",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR23",
      "unstructured": "Esteva FJ, Yu D, Hung MC, Hortobagyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7:98–107",
      "volume": "7",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nm0311-262",
      "author": "A Farrell",
      "doi-asserted-by": "publisher",
      "first-page": "262",
      "journal-title": "Nat Med",
      "key": "1010_CR24",
      "unstructured": "Farrell A (2011) A close look at cancer. Nat Med 17:262–265",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1093/jnci/djp477",
      "author": "B Freidlin",
      "doi-asserted-by": "publisher",
      "first-page": "152",
      "journal-title": "J Natl Cancer Inst",
      "key": "1010_CR25",
      "unstructured": "Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102:152–160",
      "volume": "102",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.ccr.2010.11.033",
      "author": "DE Gerber",
      "doi-asserted-by": "publisher",
      "first-page": "548",
      "journal-title": "Cancer Cell",
      "key": "1010_CR26",
      "unstructured": "Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18:548–551",
      "volume": "18",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nature09764",
      "author": "ED Green",
      "doi-asserted-by": "publisher",
      "first-page": "204",
      "journal-title": "Nature",
      "key": "1010_CR27",
      "unstructured": "Green ED, Guyer MS (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470:204–213",
      "volume": "470",
      "year": "2011"
    },
    {
      "DOI": "10.5858/2010-0734-RAIR.1",
      "author": "AM Gruver",
      "doi-asserted-by": "crossref",
      "first-page": "544",
      "journal-title": "Arch Pathol Lab Med",
      "key": "1010_CR28",
      "unstructured": "Gruver AM, Portier BP, Tubbs RR (2011) Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med 135:544–557",
      "volume": "135",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nrd1552-c1",
      "author": "J Hall",
      "doi-asserted-by": "publisher",
      "first-page": "988",
      "journal-title": "Nat Rev Drug Discov",
      "key": "1010_CR29",
      "unstructured": "Hall J, Dennler P, Haller S, Pratsinis A, Sauberli K, Towbin H, Walthe K, Woytschak J (2010) Genomics drugs in clinical trials. Nat Rev Drug Discov 9:988",
      "volume": "9",
      "year": "2010"
    },
    {
      "DOI": "10.1677/erc.0.0090075",
      "author": "M Harries",
      "doi-asserted-by": "publisher",
      "first-page": "75",
      "journal-title": "Endocr Relat Cancer",
      "key": "1010_CR30",
      "unstructured": "Harries M, Smith I (2002) The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9:75–85",
      "volume": "9",
      "year": "2002"
    },
    {
      "DOI": "10.1038/nrd3181-c1",
      "author": "T Harris",
      "doi-asserted-by": "publisher",
      "first-page": "660",
      "journal-title": "Nat Rev Drug Discov",
      "key": "1010_CR31",
      "unstructured": "Harris T (2010) Gene and drug matrix for personalized cancer therapy. Nat Rev Drug Discov 9:660",
      "volume": "9",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nrclinonc.2010.227",
      "author": "L Hood",
      "doi-asserted-by": "publisher",
      "first-page": "184",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR32",
      "unstructured": "Hood L, Friend SH (2011) Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 8:184–187",
      "volume": "8",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nrclinonc.2011.14",
      "author": "L Hutchinson",
      "doi-asserted-by": "publisher",
      "first-page": "121",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR33",
      "unstructured": "Hutchinson L (2011) Personalized cancer medicine: era of promise and progress. Nat Rev Clin Oncol 8:121",
      "volume": "8",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nature08987",
      "author": "ICGC",
      "doi-asserted-by": "publisher",
      "first-page": "993",
      "journal-title": "Nature",
      "key": "1010_CR34",
      "unstructured": "ICGC (2010) International network of cancer genome projects. Nature 464:993–998",
      "volume": "464",
      "year": "2010"
    },
    {
      "DOI": "10.1200/JCO.2006.06.7637",
      "author": "WH Isacoff",
      "doi-asserted-by": "publisher",
      "first-page": "1665",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR35",
      "unstructured": "Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA (2007) Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol 25:1665–1669",
      "volume": "25",
      "year": "2007"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-07-5200",
      "author": "A Jimeno",
      "doi-asserted-by": "publisher",
      "first-page": "2841",
      "journal-title": "Cancer Res",
      "key": "1010_CR36",
      "unstructured": "Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M (2008) Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 68:2841–2849",
      "volume": "68",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nature09627",
      "author": "CM Johannessen",
      "doi-asserted-by": "publisher",
      "first-page": "968",
      "journal-title": "Nature",
      "key": "1010_CR37",
      "unstructured": "Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972",
      "volume": "468",
      "year": "2010"
    },
    {
      "DOI": "10.1126/science.1164368",
      "author": "S Jones",
      "doi-asserted-by": "publisher",
      "first-page": "1801",
      "journal-title": "Science",
      "key": "1010_CR39",
      "unstructured": "Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806",
      "volume": "321",
      "year": "2008"
    },
    {
      "DOI": "10.1056/NEJMoa0804385",
      "author": "CS Karapetis",
      "doi-asserted-by": "publisher",
      "first-page": "1757",
      "journal-title": "N Engl J Med",
      "key": "1010_CR40",
      "unstructured": "Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765",
      "volume": "359",
      "year": "2008"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-10-0880",
      "author": "SN Khleif",
      "doi-asserted-by": "publisher",
      "first-page": "3299",
      "journal-title": "Clin Cancer Res",
      "key": "1010_CR41",
      "unstructured": "Khleif SN, Doroshow JH, Hait WN (2010) AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16:3299–3318",
      "volume": "16",
      "year": "2010"
    },
    {
      "key": "1010_CR42",
      "unstructured": "Kim ES, Herbst1 RS et al. (2011) The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 1"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-06-0544",
      "author": "K Kimura",
      "doi-asserted-by": "publisher",
      "first-page": "4925",
      "journal-title": "Clin Cancer Res",
      "key": "1010_CR43",
      "unstructured": "Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K (2006) Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12:4925–4932",
      "volume": "12",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.prp.2009.08.003",
      "author": "A Kovacs",
      "doi-asserted-by": "publisher",
      "first-page": "39",
      "journal-title": "Pathol Res Pract",
      "key": "1010_CR44",
      "unstructured": "Kovacs A, Stenman G (2010) HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol Res Pract 206:39–42",
      "volume": "206",
      "year": "2010"
    },
    {
      "DOI": "10.5694/j.1326-5377.2009.tb02592.x",
      "author": "CK Lee",
      "doi-asserted-by": "crossref",
      "first-page": "631",
      "journal-title": "Med J Aust",
      "key": "1010_CR45",
      "unstructured": "Lee CK, Lord SJ, Coates AS, Simes RJ (2009) Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust 190:631–636",
      "volume": "190",
      "year": "2009"
    },
    {
      "DOI": "10.1200/JCO.2004.05.055",
      "author": "A Liede",
      "doi-asserted-by": "publisher",
      "first-page": "735",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR46",
      "unstructured": "Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1001/jama.2011.473",
      "author": "DC Link",
      "doi-asserted-by": "publisher",
      "first-page": "1568",
      "journal-title": "JAMA",
      "key": "1010_CR47",
      "unstructured": "Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RH, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O’Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK, Mardis ER (2011) Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305:1568–1576",
      "volume": "305",
      "year": "2011"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-10-2632",
      "author": "PM LoRusso",
      "doi-asserted-by": "publisher",
      "first-page": "5951",
      "journal-title": "Clin Cancer Res",
      "key": "1010_CR48",
      "unstructured": "LoRusso PM, Schnipper LE, Stewart DJ, Boerner SA, Averbuch SD, Wolf W (2010) Translating clinical trials into meaningful outcomes. Clin Cancer Res 16:5951–5955",
      "volume": "16",
      "year": "2010"
    },
    {
      "DOI": "10.1200/JCO.2009.27.4944",
      "author": "LE Macconaill",
      "doi-asserted-by": "publisher",
      "first-page": "5219",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR49",
      "unstructured": "Macconaill LE, Garraway LA (2010) Clinical implications of the cancer genome. J Clin Oncol 28:5219–5228",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1371/journal.pone.0007887",
      "author": "LE MacConaill",
      "doi-asserted-by": "publisher",
      "first-page": "e7887",
      "journal-title": "PLoS One",
      "key": "1010_CR50",
      "unstructured": "MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887",
      "volume": "4",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nm.2311",
      "author": "IJ Majewski",
      "doi-asserted-by": "publisher",
      "first-page": "304",
      "journal-title": "Nat Med",
      "key": "1010_CR51",
      "unstructured": "Majewski IJ, Bernards R (2011) Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 17:304–312",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.2009.22.3701",
      "author": "SJ Mandrekar",
      "doi-asserted-by": "publisher",
      "first-page": "4027",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR52",
      "unstructured": "Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27:4027–4034",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nrd3360",
      "author": "M McClellan",
      "doi-asserted-by": "publisher",
      "first-page": "79",
      "journal-title": "Nat Rev Drug Discov",
      "key": "1010_CR53",
      "unstructured": "McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D (2011) An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov 10:79–80",
      "volume": "10",
      "year": "2011"
    },
    {
      "DOI": "10.1056/NEJMp1014256",
      "author": "U McDermott",
      "doi-asserted-by": "publisher",
      "first-page": "340",
      "journal-title": "N Engl J Med",
      "key": "1010_CR54",
      "unstructured": "McDermott U, Downing JR, Stratton MR (2011) Genomics and the continuum of cancer care. N Engl J Med 364:340–350",
      "volume": "364",
      "year": "2011"
    },
    {
      "DOI": "10.1517/14622416.3.5.603",
      "author": "IK Mellinghoff",
      "doi-asserted-by": "publisher",
      "first-page": "603",
      "journal-title": "Pharmacogenomics",
      "key": "1010_CR55",
      "unstructured": "Mellinghoff IK, Sawyers CL (2002) The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 3:603–623",
      "volume": "3",
      "year": "2002"
    },
    {
      "DOI": "10.1038/nrclinonc.2010.230",
      "author": "J Mendelsohn",
      "doi-asserted-by": "publisher",
      "first-page": "133",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR56",
      "unstructured": "Mendelsohn J, Tursz T, Schilsky RL, Lazar V (2011) WIN Consortium-challenges and advances. Nat Rev Clin Oncol 8:133–134",
      "volume": "8",
      "year": "2011"
    },
    {
      "DOI": "10.1038/ncponc0925",
      "author": "CW Michalski",
      "doi-asserted-by": "publisher",
      "first-page": "526",
      "journal-title": "Nat Clin Pract Oncol",
      "key": "1010_CR57",
      "unstructured": "Michalski CW, Weitz J, Buchler MW (2007) Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 4:526–535",
      "volume": "4",
      "year": "2007"
    },
    {
      "DOI": "10.1200/JCO.2006.07.9525",
      "author": "MJ Moore",
      "doi-asserted-by": "publisher",
      "first-page": "1960",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR58",
      "unstructured": "Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966",
      "volume": "25",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.bcp.2010.04.017",
      "author": "KL Nathanson",
      "doi-asserted-by": "publisher",
      "first-page": "755",
      "journal-title": "Biochem Pharmacol",
      "key": "1010_CR59",
      "unstructured": "Nathanson KL (2010) Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol 80:755–761",
      "volume": "80",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nature09626",
      "author": "R Nazarian",
      "doi-asserted-by": "publisher",
      "first-page": "973",
      "journal-title": "Nature",
      "key": "1010_CR60",
      "unstructured": "Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977",
      "volume": "468",
      "year": "2010"
    },
    {
      "DOI": "10.1093/jnci/djq319",
      "author": "NJ Nelson",
      "doi-asserted-by": "publisher",
      "first-page": "1217",
      "journal-title": "J Natl Cancer Inst",
      "key": "1010_CR61",
      "unstructured": "Nelson NJ (2010) Adaptive clinical trial design: has its time come? J Natl Cancer Inst 102:1217–1218",
      "volume": "102",
      "year": "2010"
    },
    {
      "DOI": "10.1016/S0140-6736(01)06651-X",
      "author": "JP Neoptolemos",
      "doi-asserted-by": "publisher",
      "first-page": "1576",
      "journal-title": "Lancet",
      "key": "1010_CR62",
      "unstructured": "Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585",
      "volume": "358",
      "year": "2001"
    },
    {
      "DOI": "10.1093/jnci/djq463",
      "author": "A Ocana",
      "doi-asserted-by": "publisher",
      "first-page": "16",
      "journal-title": "J Natl Cancer Inst",
      "key": "1010_CR63",
      "unstructured": "Ocana A, Tannock IF (2011) When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst 103:16–20",
      "volume": "103",
      "year": "2011"
    },
    {
      "DOI": "10.1001/jama.297.3.267",
      "author": "H Oettle",
      "doi-asserted-by": "publisher",
      "first-page": "267",
      "journal-title": "JAMA",
      "key": "1010_CR64",
      "unstructured": "Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277",
      "volume": "297",
      "year": "2007"
    },
    {
      "DOI": "10.1007/s00439-011-0990-0",
      "doi-asserted-by": "publisher",
      "key": "1010_CR65",
      "unstructured": "Pajic M, Scarlett CJ, Chang DK, Sutherland RL, Biankin AV (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet. doi:10.1007/s00439-011-0990-0"
    },
    {
      "DOI": "10.1038/nm.2166",
      "author": "N Palanisamy",
      "doi-asserted-by": "publisher",
      "first-page": "793",
      "journal-title": "Nat Med",
      "key": "1010_CR66",
      "unstructured": "Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793–798",
      "volume": "16",
      "year": "2010"
    },
    {
      "DOI": "10.1126/science.1164382",
      "author": "DW Parsons",
      "doi-asserted-by": "publisher",
      "first-page": "1807",
      "journal-title": "Science",
      "key": "1010_CR67",
      "unstructured": "Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812",
      "volume": "321",
      "year": "2008"
    },
    {
      "DOI": "10.1200/JCO.2009.21.9022",
      "author": "PA Philip",
      "doi-asserted-by": "publisher",
      "first-page": "5660",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR68",
      "unstructured": "Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O’Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27:5660–5669",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nm0311-283",
      "author": "K Polyak",
      "doi-asserted-by": "publisher",
      "first-page": "283",
      "journal-title": "Nat Med",
      "key": "1010_CR69",
      "unstructured": "Polyak K, Garber J (2011) Targeting the missing links for cancer therapy. Nat Med 17:283–284",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nm.2305",
      "author": "M Rodríguez-Paredes",
      "doi-asserted-by": "publisher",
      "first-page": "330",
      "journal-title": "Nat Med",
      "key": "1010_CR70",
      "unstructured": "Rodríguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17:330–339",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1016/0197-2456(93)90028-C",
      "author": "WF Rosenberger",
      "doi-asserted-by": "publisher",
      "first-page": "471",
      "journal-title": "Control Clin Trials",
      "key": "1010_CR71",
      "unstructured": "Rosenberger WF, Lachin JM (1993) The use of response-adaptive designs in clinical trials. Control Clin Trials 14:471–484",
      "volume": "14",
      "year": "1993"
    },
    {
      "DOI": "10.1081/CNV-200032974",
      "author": "H Safran",
      "doi-asserted-by": "publisher",
      "first-page": "706",
      "journal-title": "Cancer Invest",
      "key": "1010_CR72",
      "unstructured": "Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22:706–712",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1200/JCO.2005.01.112",
      "author": "DJ Sargent",
      "doi-asserted-by": "publisher",
      "first-page": "2020",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR73",
      "unstructured": "Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020–2027",
      "volume": "23",
      "year": "2005"
    },
    {
      "DOI": "10.1038/nrd3181",
      "author": "RL Schilsky",
      "doi-asserted-by": "publisher",
      "first-page": "363",
      "journal-title": "Nat Rev Drug Discov",
      "key": "1010_CR74",
      "unstructured": "Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9:363–366",
      "volume": "9",
      "year": "2010"
    },
    {
      "DOI": "10.1093/annonc/mdp552",
      "author": "B Seruga",
      "doi-asserted-by": "publisher",
      "first-page": "1411",
      "journal-title": "Ann Oncol",
      "key": "1010_CR75",
      "unstructured": "Seruga B, Hertz PC, Wang L, Booth CM, Cescon DW, Krzyzanowska M, Tannock IF (2010) Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol 21:1411–1418",
      "volume": "21",
      "year": "2010"
    },
    {
      "DOI": "10.2174/156800911795655921",
      "author": "MP Shekhar",
      "doi-asserted-by": "crossref",
      "first-page": "613",
      "journal-title": "Curr Cancer Drug Targets",
      "key": "1010_CR76",
      "unstructured": "Shekhar MP (2011) Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 11:613–623",
      "volume": "11",
      "year": "2011"
    },
    {
      "DOI": "10.1517/17425240903544462",
      "author": "SL Showalter",
      "doi-asserted-by": "publisher",
      "first-page": "273",
      "journal-title": "Expert Opin Drug Deliv",
      "key": "1010_CR77",
      "unstructured": "Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ (2010) Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv 7:273–284",
      "volume": "7",
      "year": "2010"
    },
    {
      "DOI": "10.1056/NEJMcibr1013704",
      "author": "DB Solit",
      "doi-asserted-by": "publisher",
      "first-page": "772",
      "journal-title": "N Engl J Med",
      "key": "1010_CR78",
      "unstructured": "Solit DB, Rosen N (2011) Resistance to BRAF inhibition in melanomas. N Engl J Med 364:772–774",
      "volume": "364",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nature07943",
      "author": "MR Stratton",
      "doi-asserted-by": "publisher",
      "first-page": "719",
      "journal-title": "Nature",
      "key": "1010_CR79",
      "unstructured": "Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458:719–724",
      "volume": "458",
      "year": "2009"
    },
    {
      "DOI": "10.1200/JCO.2009.23.3098",
      "author": "J Tabernero",
      "doi-asserted-by": "publisher",
      "first-page": "5487",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR80",
      "unstructured": "Tabernero J, Macarulla T (2009) Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol 27:5487–5491",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nature07385",
      "author": "TCGA CGARN",
      "doi-asserted-by": "crossref",
      "first-page": "1061",
      "journal-title": "Nature",
      "key": "1010_CR81",
      "unstructured": "TCGA CGARN (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068",
      "volume": "455",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nature07385",
      "author": "TCGA",
      "doi-asserted-by": "publisher",
      "first-page": "1061",
      "journal-title": "Nature",
      "key": "1010_CR82",
      "unstructured": "TCGA (2008b) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068",
      "volume": "455",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nrclinonc.2010.222",
      "author": "T Tursz",
      "doi-asserted-by": "publisher",
      "first-page": "177",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR83",
      "unstructured": "Tursz T, Andre F, Lazar V, Lacroix L, Soria JC (2011) Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 8:177–183",
      "volume": "8",
      "year": "2011"
    },
    {
      "DOI": "10.1016/S0002-9440(10)63329-9",
      "author": "MS van der Heijden",
      "doi-asserted-by": "publisher",
      "first-page": "651",
      "journal-title": "Am J Pathol",
      "key": "1010_CR84",
      "unstructured": "van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE (2004) Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165:651–657",
      "volume": "165",
      "year": "2004"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-05-1048",
      "author": "MS van der Heijden",
      "doi-asserted-by": "publisher",
      "first-page": "7508",
      "journal-title": "Clin Cancer Res",
      "key": "1010_CR85",
      "unstructured": "van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515",
      "volume": "11",
      "year": "2005"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-10-0893",
      "author": "MC Villarroel",
      "doi-asserted-by": "publisher",
      "first-page": "3",
      "journal-title": "Mol Cancer Ther",
      "key": "1010_CR86",
      "unstructured": "Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M (2011) Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10:3–8",
      "volume": "10",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.2009.26.5983",
      "author": "DD Von Hoff",
      "doi-asserted-by": "publisher",
      "first-page": "4877",
      "journal-title": "J Clin Oncol",
      "key": "1010_CR87",
      "unstructured": "Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877–4883",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nrclinonc.2010.97",
      "author": "DL Wheeler",
      "doi-asserted-by": "publisher",
      "first-page": "493",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR88",
      "unstructured": "Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493–507",
      "volume": "7",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nrclinonc.2011.2",
      "author": "II Wistuba",
      "doi-asserted-by": "publisher",
      "first-page": "135",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "1010_CR89",
      "unstructured": "Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS (2011) Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 8:135–141",
      "volume": "8",
      "year": "2011"
    },
    {
      "DOI": "10.1038/ng1942",
      "author": "B Xia",
      "doi-asserted-by": "publisher",
      "first-page": "159",
      "journal-title": "Nat Genet",
      "key": "1010_CR90",
      "unstructured": "Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161",
      "volume": "39",
      "year": "2007"
    }
  ],
  "reference-count": 90,
  "references-count": 90,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s00439-011-1010-0"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Somatic variation and cancer: therapies lost in the mix"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "130"
}